Equities

Eve & Co Inc

EVE.H:NEX

Eve & Co Inc

Actions
  • Price (CAD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eve & Co Incorporated is a Canada-based company, which holds cultivation and processing licenses for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil. It is a licensed producer of medicinal marijuana. It also provides educational information and online support for its customers and first-time buyers. Its products include The Boss Bath Bomb, The Dreamer Bath Bomb, The Lover Bath Bomb, The Optimist CBD Bath Bomb, Indica Blend, Sativa Blend, The Boss, The Confidant, The Creator, The Lover, The Adventurer, The Advocate, and The Free Spirit. Its wholly owned subsidiary is Natural MedCo Ltd. The Boss Bath Bomb has an invigorating blend of sweet orange, lemon, and grapefruit essential oils that come together to enhance and lift mood, reduce stress, and stimulate circulation. The Dreamer Bath Bomb has calming lavender and chamomile essential oils that help to reduce stress and anxiety and promote calmness.

  • Revenue in CAD (TTM)7.77m
  • Net income in CAD-5.92m
  • Incorporated2014
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genix Pharmaceuticals Corp10.83k-4.23m2.96m--------273.77-0.0714-0.07140.0002-0.02020.00490.05021.89---191.99-54.69-476.20-68.5923.08---39,036.01-5,345.880.0541-10.33-------50.60-309.27------
Therma Bright Inc25.80k-2.88m3.16m----1.72--122.60-0.0115-0.01150.00010.00580.00760.00230.115---84.40-220.66-165.23-444.5798.45---11,152.48-10,853.160.0447-184.520.0411---82.8611.1335.93--40.15--
Aequus Pharmaceuticals Inc215.21k-2.88m3.32m12.00------15.43-0.0217-0.02170.0016-0.03730.20941.2311.31---280.53-97.96---293.3158.26---1,339.39-141.530.0724-16.307.83---81.53-28.977.64------
Marvel Biosciences Corp0.00-2.51m3.39m-----------0.0632-0.06320.00-0.06170.00-------372.25-----------------26.43--------10.29------
Quest PharmaTech Inc0.00-22.26m3.39m0.00--0.0511-----0.1319-0.13190.000.39130.00-------28.4623.29-28.8627.25-----------0.05550.0149------91.38------
Hemostemix Inc0.00-2.50m3.49m-----------0.0303-0.03030.00-0.08460.00-------642.29-599.98---------------3.99--------52.21------
Eve & Co Inc7.77m-5.92m3.74m--------0.4817-0.2055-0.20550.26980.7330.15190.74938.73---11.58---24.24---3.10---76.22--0.062-5.050.4892--2.94---71.97------
Appili Therapeutics Inc1.15m-5.34m4.25m8.00------3.70-0.044-0.0440.0095-0.08110.5047--2.12---234.31-117.41---173.66-----464.23-3,037.15---5.32-----75.97--63.20---43.04--
Data as of Mar 28 2022. Currency figures normalised to Eve & Co Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.